BRC-002

**BRC-002** is an investigational, orally administered, high-cannabidiol botanical drug developed by BRC Therapeutics for pain and associated symptoms of complex regional pain syndrome. It is a proprietary, prescription-grade Cannabis sativa L. extract containing major and minor cannabinoids at defined ratios, reported to include cannabidiolic acid, tetrahydrocannabinolic acid, and other minor cannabinoids, with less than 0.3% tetrahydrocannabinol. The product is intended to provide multimodal cannabinoid-mediated relief of pain and comorbid symptoms, although its exact active-constituent ratios and target-level pharmacology have not been publicly disclosed. BRC-002 has FDA orphan-drug designation for complex regional pain syndrome and is being evaluated in clinical studies for complex regional pain syndrome and idiopathic restless legs syndrome. ([brctherapeutics.com](https://brctherapeutics.com/pressrelease/brc-therapeutics-announces-investigational-new-drug-application-for-brc-002-cleared-by-fda/))

Other names

High CBD cannabis extractHigh cannabidiol cannabis extract